Global Short Bowel Syndrome (SBS) Market Growth (Status and Outlook) 2023-2029

Global Short Bowel Syndrome (SBS) Market Growth (Status and Outlook) 2023-2029

Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.

LPI (LP Information)' newest research report, the “Short Bowel Syndrome (SBS) Industry Forecast” looks at past sales and reviews total world Short Bowel Syndrome (SBS) sales in 2022, providing a comprehensive analysis by region and market sector of projected Short Bowel Syndrome (SBS) sales for 2023 through 2029. With Short Bowel Syndrome (SBS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Short Bowel Syndrome (SBS) industry.

This Insight Report provides a comprehensive analysis of the global Short Bowel Syndrome (SBS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Short Bowel Syndrome (SBS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Short Bowel Syndrome (SBS) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Short Bowel Syndrome (SBS) and breaks down the forecast by type, by sale channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Short Bowel Syndrome (SBS).

The global Short Bowel Syndrome (SBS) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.

This report presents a comprehensive overview, market shares, and growth opportunities of Short Bowel Syndrome (SBS) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Oral Route
Parental Route

Segmentation by sale channel
Hospitals
Clinics
Retail Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.